Literature DB >> 15262174

Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy?

Vanessa A Rodie1, Dilys J Freeman, Naveed Sattar, Ian A Greer.   

Abstract

Complications of pregnancy, particularly pre-eclampsia (PET) and intra-uterine growth restriction (IUGR) have been associated with future maternal cardiovascular disease (CVD). Pre-eclampsia, characterised by insulin resistance, widespread endothelial damage and dysfunction, coagulation defects and increased systemic inflammatory response, shares many risk factors with CVD. This review describes the pathology of PET and the maternal metabolic response and discusses the possible underlying mechanisms common to CVD and PET. The contributions of pre-existing risk factors and of the exaggerated atherogenic-like response seen in PET persisting post-partum to future CVD are considered. The potential for interventions based on early assessment of cardiovascular risk is addressed. We conclude that despite the low immediate cardiovascular risk in a population of young women, a pregnancy with multiple complications including PET, premature delivery and IUGR, carries a seven-fold additive risk of future disease. These women may be an appropriate cohort for CVD risk screening and for possible intervention. Copyright 2004 Elsevier Ireland Ltd

Entities:  

Mesh:

Year:  2004        PMID: 15262174     DOI: 10.1016/j.atherosclerosis.2004.01.038

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  61 in total

1.  Prepregnancy cardiometabolic and inflammatory risk factors and subsequent risk of hypertensive disorders of pregnancy.

Authors:  Monique M Hedderson; Jeanne A Darbinian; Sneha B Sridhar; Charles P Quesenberry
Journal:  Am J Obstet Gynecol       Date:  2012-05-23       Impact factor: 8.661

2.  Pre-eclampsia is associated with sleep-disordered breathing and endothelial dysfunction.

Authors:  D Yinon; L Lowenstein; S Suraya; R Beloosesky; O Zmora; A Malhotra; G Pillar
Journal:  Eur Respir J       Date:  2006-02       Impact factor: 16.671

Review 3.  Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention.

Authors:  Kirsten Lawrence Cleary; Kelly Roney; Maged Costantine
Journal:  Semin Perinatol       Date:  2014-10-12       Impact factor: 3.300

4.  Association of number of live births with left ventricular structure and function. The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Nisha I Parikh; Donald M Lloyd-Jones; Hongyan Ning; Pamela Ouyang; Joseph F Polak; João A Lima; David Bluemke; Murray A Mittleman
Journal:  Am Heart J       Date:  2012-03       Impact factor: 4.749

Review 5.  Association of microparticles and preeclampsia.

Authors:  Fabiana K Marques; Fernanda M F Campos; Lirlândia P Sousa; Andréa Teixeira-Carvalho; Luci M S Dusse; Karina B Gomes
Journal:  Mol Biol Rep       Date:  2013-05-06       Impact factor: 2.316

Review 6.  How does preeclampsia predispose to future cardiovascular disease?

Authors:  Dawn C Scantlebury; Sharonne N Hayes
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

7.  Autonomic Dysfunction in Preeclampsia: A Systematic Review.

Authors:  Dalia Yousif; Ioannis Bellos; Ana Isabel Penzlin; Mido Max Hijazi; Ben Min-Woo Illigens; Alexandra Pinter; Timo Siepmann
Journal:  Front Neurol       Date:  2019-08-06       Impact factor: 4.003

8.  Late pregnancy complications in polycystic ovarian syndrome.

Authors:  I Katsikis; M Kita; A Karkanaki; N Prapas; D Panidis
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

Review 9.  Obesity and cardiovascular disease in women.

Authors:  Camila Manrique-Acevedo; Bhavana Chinnakotla; Jaume Padilla; Luis A Martinez-Lemus; David Gozal
Journal:  Int J Obes (Lond)       Date:  2020-02-17       Impact factor: 5.095

10.  Genetic dissection of the pre-eclampsia susceptibility locus on chromosome 2q22 reveals shared novel risk factors for cardiovascular disease.

Authors:  Matthew P Johnson; Shaun P Brennecke; Christine E East; Thomas D Dyer; Linda T Roten; J Michael Proffitt; Phillip E Melton; Mona H Fenstad; Tia Aalto-Viljakainen; Kaarin Mäkikallio; Seppo Heinonen; Eero Kajantie; Juha Kere; Hannele Laivuori; Rigmor Austgulen; John Blangero; Eric K Moses
Journal:  Mol Hum Reprod       Date:  2013-02-18       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.